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        CD8  T cells play a pivotal role for the clear-
ance of viruses and other intracellular pathogens. 
Although the immune system is confronted with 
a vast variety of pathogen-specifi  c determinants, 
T cell responses to viral infections have been 
found to be directed against a rather small num-
ber of antigens. Regarding their overall size, T cell 
responses against diff  erent epitopes can be ar-
ranged in an immunodominance hierarchy. Fun-
damental conclusions have been drawn from 
experiments investigating infl  uenza virus, lym-
pho  cytic choriomeningitis virus (LCMV), or 
  Listeria mono  cytogenes   in infection models or by 
using peptide-pulsed DCs and adoptively trans-
ferred TCR transgenic T cells (  1  ), indicating 
that T cells can compete at the level of APCs. 
Although the competition of T cells of the same 
specifi  city has been clearly demonstrated, com-
petition between T cells of diff  erent specifi  cities 
(cross-competition) is still controversial (  2  ). There 
are only a few reports in the literature that 
argue either for (HSV and infl  uenza) or against 
(LCMV) a relevance of cross-competition dur-
ing the primary induction of an antiviral immune 
response (  3  –  5  ). 
  Several important features for the develop-
ment of immunodominance hierarchies of T 
cells have been identifi  ed, as follows: (a) CD8  
T cells of the same specifi  city compete for access 
to APCs, and (b) T cell expansion depends on 
the precursor frequency, (c) is aff  ected by T cell 
receptor affi   nity, and (d) can be controlled by 
APC killing (LCMV) or (e) in the absence of 
APC killing (infl  uenza) by downmodulation 
of antigen from the APC or competition for 
antiapoptotic cytokines (  6  –  8  ). Importantly, the 
  immunodominance hierarchy of T cells can 
dra    matically change between primary and sec-
ondary immune responses. In the case of infl  u-
enza virus, this has been imputed to diff  erential 
antigen presentation during primary and sec-
ondary immune responses (  9  ). 
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  CD8 T cell responses directed against multiple pathogen-derived epitopes are characterized 
by defi  ned immunodominance hierarchy patterns. A possible explanation for this 
phenomenon is that CD8 T cells of different specifi  cities compete for access to epitopes 
on antigen-presenting cells, and that the outcome of this so-called cross-competition 
refl  ects the number of induced T cells. In our study using a vaccinia virus infection model, 
we found that T cell cross-competition is highly relevant during boost vaccination, thereby 
shaping the immunodominance hierarchy in the recall. We demonstrate that competition was 
of no importance during priming and was unaffected by the applied route of immunization. 
It strongly depended on the timing of viral antigen expression in infected APCs, and it was 
characterized by poor proliferation of T cells recognizing epitopes derived from late viral 
proteins. To our knowledge, this is the fi  rst demonstration of the functional importance 
of T cell cross-competition during a viral infection. Our fi  ndings provide a basis for 
novel strategies for how boost vaccination to defi  ned antigens can be selectively improved. 
They give important new insights into the design of more effi  cient poxviral vectors 
for immunotherapy. 2188 CROSS-COMPETITION SHAPES IMMUNODOMINANCE HIERARCHY | Kastenmuller et al.
intermediate, and late activity. Previous work suggested that 
the immunogenicity of recombinant proteins produced by VV 
is infl  uenced by the promoter driving the respective genes (  16  ). 
Therefore, we presumed a specifi  c impact of viral gene ex-
pression on the immunodominance hierarchy of early and late 
viral proteins. 
  Our experiments show that the induction and strength of 
primary CD8  T cell responses against various VV-specifi  c ep-
itopes in a naive host is largely independent from simultaneous 
priming of T cells specifi  c for other antigenic determinants 
delivered by the virus. However, during boost vaccinations, 
T cell cross-competition seems to be a major regulator of the 
expansion of virus-specifi  c T cells. In particular, T cells recog-
nizing determinants derived from late viral proteins had a clear 
disadvantage to proliferate during secondary responses. 
  However, the effi   ciency of boost vaccinations was strongly 
enhanced by using promoters that are active early during the 
viral life cycle. Our work has important implications for the 
use and the future design of viral vectors for immunotherapy. 
    RESULTS   
  Priming of T cells is independent of T cell competition 
  To investigate the role of T cell cross-competition on shaping 
the T cell response to VV, we compared the immune responses 
against several replication-competent and -defi  cient strains, 
as well as recombinant MVA viruses. MVA constructs either 
expressed or lacked antigens bearing strongly immunogenic 
  Until now, most of the work on immunodominance has 
been done on viruses with relatively small genomes (10  –  20 kb). 
Large DNA viruses, like Herpes or Poxviruses (    200 kb), re-
present a great challenge for the analysis of immunodominance. 
However, they also off  er the possibility to identify crucial 
mechanisms of immunodominance because the immune 
  system exceedingly shapes the immune response by trimming 
it down to reactivity against a few epitopes. We and others 
recently identifi  ed HLA-A2  –   and H2-K  b  /D  b    –  restricted pox-
virus determinants, which were derived from a large variety 
of proteins (  10  –  15  ). Usage of these epitopes should allow us 
to identify and analyze the underlying mechanisms of immuno-
dominance in poxviral T cell responses. We used diff  erent 
strains of vaccina virus (VV; modifi  ed VV Ankara [MVA], 
chorioallantois VV Ankara [CVA], and Wyeth) for our infec-
tion experiments in C57BL/6 and HLA-A2 transgenic mice 
(HHD mice). In contrast to the replication-competent VV 
strains CVA and Wyeth, MVA is unable to replicate in mam-
malian cells. Therefore, the infection is abortive and is largely 
synchronized with the advantage to minimize an overlap of 
the phases of viral gene expression by cells that are infected 
at diff  erent time points during virus spreading. MVA is al-
ready used in clinical trials as a recombinant vector, and it is 
also considered as a next generation poxvirus vaccine. An in-
teresting hallmark of poxviruses is the cascade-like course of 
antigen expression. There are three distinct phases of viral 
gene expression driven by distinct promoters with early, 
  Figure 1.     T cell cross-competition is absent during priming with MVA. (A) The applied gating strategy for analysis of viable (EMA-negative) CD8 - 
and CD62L-low IFN-       –  producing T cells (corresponding number is encircled). Numbers in the top left corner indicate the order of applied gates. (B) HHD 
mice were vaccinated i.p. (10  7   IU) with rec MVA or MVA WT. (C) Table shows early and late viral antigens and MHC-I restriction of the respective epitopes. 
(D) C57BL/6 mice were vaccinated i.p. (10  8   IU) with MVA WT, MVA P7.5 OVA, or MVA deletion mutant (MVA      B8R). 8 d after vaccination, tyrosinase-, 
her-2/neu  –  , OVA-, and vector-specifi  c CD8  T cell responses were analyzed by intracellular cytokine staining of splenocytes after a brief incubation with 
the A*0201-restricted tyrosinase peptide Tyr  369 ,  Her-2/neu 435 ,  MVA-specifi  c peptides A6L  6 ,  B22R 79 ,  C7L 74 ,  D12L 251 ,  I1L 211 ,  H3L 184 ,  or  H2 b   restricted  OVA 257  
(SIINFEKL), MVA-specifi  c peptides A3L  270 ,  A8R 189 ,  B8R 20 ,  K3L 6  , or an irrelevant peptide. Filled arrows indicate additional responses; open arrows represent 
missing responses compared with MVA WT. Results are representative of three independent experiments.   n     4.     JEM VOL. 204, September 3, 2007 
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compared with the primary response. Interestingly, early 
gene product B22R  79  -specifi  c T cells expanded vigorously 
during the secondary immunization and became the domi-
nant T cell population among the tested epitope specifi  cities. 
This severe switch is surprising because it contradicts the pre-
diction that T cells dominating the primary response should 
also dominate the secondary response if memory precursor 
frequencies were merely the critical factor for the immuno-
dominance hierarchy of recall responses. In C57BL/6 mice, 
the primary response is dominated by T cells specifi  c for B8R  20  , 
which is derived from an early gene product. If early antigen 
expression supports recall expansion, boosting of C57BL/6 
mice with MVA WT should still support the recall expansion 
of B8R  20  -specifi  c T cells. Indeed, boosting with MVA WT 
led to a strong expansion of B8R  20  -specifi  c T cells (  Fig. 2 B  ). 
From these experiments, we hypothesized (a) that T cells spe-
cifi  c for early viral proteins might be able to suppress the expan-
sion of other virus-specifi  c T cells, and (b) that T cells specifi  c 
for late viral proteins should have a disadvantage to proliferate 
and expand during recall responses. 
epitopes compared with WT virus (MVA WT). We hypoth-
esized that the quantity of induced T cells would be infl  uenced 
by additional introduction or removal of immuno  dominant 
epitopes if T cell cross-competition was functionally impor-
tant during priming. We compared the CD8  T cell responses 
directed against a variety of virus-specifi  c epitopes.   Fig. 1   
shows the relative numbers of T cells producing IFN-      after 
in vitro restimulation with the respective peptides analyzed by 
intracellular cytokine staining of freshly isolated splenocytes.   
8 d after infection of HLA-A2 transgenic (HHD) mice with 
MVA WT, T cells recognizing epitopes from late gene pro-
ducts (A6L  6  , H3L  184  , and I1L  211  ) were dominating the re-
sponse (  Fig. 1 B  ). T cells recognizing epitopes derived from 
early proteins were subdominant (B22R  79  ) or close to detec-
tion limit (  <  0.1% of CD8 : C7L  74   and D12L  251  ). Recombi-
nant viruses additionally expressing human tyrosinase (MVA 
hTyr) or human Her-2/neu (MVA-Her-2/neu) induced a 
strong Tyr  369  - or moderate Her-2/neu  435    –  specifi  c response. 
However, the vector-specifi  c response remained unchanged 
compared with MVA WT. To exclude a mouse strain  –    specifi  c 
eff  ect, we also analyzed C57BL/6 mice. In these mice, the 
  cellular immune response against MVA WT is highly dom-
inated by B8R  20  -specifi  c T cells, which recognize a deter-
minant derived from an early gene product, followed by 
A3L  270  - (late gene product), K3L  6  - (early gene product), and 
A8R  189  -specifi  c (early gene product) T cells. Again, a recom-
binant virus expressing OVA (MVA P7.5 OVA) induced 
a strong additional OVA  257  -specifi  c response in these mice 
without altering the frequencies of vector-specifi  c T cells 
(  Fig. 1 D  ). Tetramer staining showed similar results (unpub-
lished data). We further constructed a mutant virus (MVA 
     B8R) with a deleted   B8R   gene (Fig. S1, available at http://
www.jem.org/cgi/content/full/jem.20070849/DC1) to in-
vestigate if the induction of B8R  20  -specifi  c T cells possibly 
interfered with the primary induction of T cells specifi  c for 
other VV epitopes. In vitro experiments confi  rmed similar 
growth kinetics for MVA      B8R and MVA WT (Fig. S2), 
excluding an attenuation of the deletion variant. MVA      B8R 
did not induce a B8R  20  -specifi  c T cell response, and other 
vector-specifi  c T cells did not compensate for that loss (  Fig. 1 D  ). 
This was also seen at low doses (10  5   infectious units [IU]; un-
published data). From these experiments, we conclude that 
the primary induction of vector-specifi  c T cells using MVA 
is not infl  uenced by the priming of other vector-induced T 
cells. The time of expression (early vs. late) of viral anti  gens did 
not correlate with their position within the immunodomi-
nance hierarchy. 
  Immunodominance hierarchy after secondary immunization 
correlates with viral gene expression 
  Next, we wanted to analyze whether the timing of antigen 
expression (early vs. late viral genes) was relevant for the 
reactivation of memory T cells. When boosting HHD mice 
with MVA WT, memory T cells recognizing epitopes derived 
from late gene products such as H3L  184   and I1L  211   did not 
expand (  Fig. 2 A  ).   A6L  6  -specifi  c T cells were not amplifi  ed 
  Figure 2.     Immunodominance hierarchy is changed after secondary 
immunization in HHD mice. (A) HHD or C57BL/6 mice were analyzed 
8 d after prime (shaded bar) or boosted 35 d after prime and analyzed 
6 d later (open bar). Mice were vaccinated i.p. with 10  8   IU. Only in HHD 
mice did B22R  79 -specifi  c T cells increase in frequency; A6L  6 -,  H3L 184 -,  and 
I1L  211 -specifi  c T cells do not proliferate during secondary immunizations. 
(B) In C57BL/6 mice, B8R  20 -specifi  c T cells dominate the primary and 
  secondary response. (C) Replication-competent virus CVA shows a shift 
similar to MVA in the immunodominance hierarchy. Results are represen-
tative of three independent experiments.   n      4.   2190 CROSS-COMPETITION SHAPES IMMUNODOMINANCE HIERARCHY | Kastenmuller et al.
viral gene expression. The interval between these phases is 
only about 1 h on the transcriptional level (  18  ). To test if 
diff  erences in viral transcription led to a relevant delay of the 
presentation of viral antigens, we established several T cell 
lines specifi  c for VV early or late protein determinants. T cells 
recognizing early determinant B22R  79   were able to effi   -
ciently lyse infected target cells 3 h after infection (  Fig. 3 A  ).   
In contrast, T cells with specifi  city for late viral proteins, 
such as H3L  184  -specifi  c T cells were not able to recognize 
infected cells before 15 h after infection. A6L  6  - and I1L  211  -
specifi  c T cell lines could not lyse infected target cells even 
at 15 h after infection (unpublished data). To gain more detailed 
information, we performed intracellular cytokine staining of 
T cells after coincubation with infected stimulator cells and 
performed detailed kinetic analyses. As shown in   Fig. 3 C  , at 
2 h after infection the majority of B22R  79  -specifi  c T cells (95%) 
were already stimulated. Again, A6L  6  - and I1L  211  -specifi  c 
  Expansion of T cells specifi  c for late gene products 
is broadly impaired 
  It has been shown that the route of vaccination can consider-
ably change the outcome of immune responses toward vaccines 
and infl  uences the immunodominance hierarchy (  17  ). There-
fore, we decided to include two clinically relevant   application 
routes, intradermal and i.m. prime and boost   immunizations, 
in our experiments. We found that irrespective of the admin-
istration route, the immunodominance hierarchy was conserved 
during priming, but again, T cells specifi  c for late viral antigens 
had a disadvantage to expand during recall responses (Fig. 
S3, available at http://www.jem.org/cgi/content/full/jem
.20070849/DC1). Nevertheless, the T cell frequencies varied 
between diff  erent vaccination routes. The strongest responses 
could be measured in the spleen after i.p. priming, followed by 
i.m. and intradermal immunizations. 
  Next, we wanted to analyze whether the poor proliferation 
of T cells specifi  c for late viral antigens during recall re-
sponses was caused by the lack of replication of MVA 
in vivo. Comparative analysis of the immune response 8 d 
after prime using MVA or the replication-competent parental 
strain CVA revealed a similar immunodominance hierarchy 
for both viruses (  Fig. 2, A and C  ). Also, in CVA-immunized 
mice, A6L  6   was immunodominant, followed by I1L  211  - and 
H3L  184  -specifi  c responses. Interestingly, we could detect a 
substantial response against B22R  79   8 d after immunization 
with CVA. 6 d after boosting, we again found suppression 
of T cell responses against late viral epitopes using this repli-
cation-competent virus (  Fig. 2 C  ). Similar results were ob-
tained in experiments using the replication-competent VV 
strain Wyeth (unpublished data). To exclude that the lack of 
recall proliferation was caused by a general malfunction of 
T cells specifi  c for epitopes derived from late gene products, 
we boosted MVA-primed mice with the respective peptides. As 
seen in Fig. S4 (available at http://www.jem.org/cgi/content/
full/jem.20070849/DC1), H3L  184  -specifi   c T cells could be 
readily amplifi  ed in vivo when mice were revaccinated with 
H3L  184   peptide. Also, B22R  79  -specifi  c T cells were expanded, 
when boosting with the respective peptide, yet to a lower 
  extent. The frequency of C7L  74  -specifi  c T cells did not exceed 
that of peptide-primed mice. In that respect, the expansion of 
MVA-primed T cells by single peptide revaccination resulted 
in a pattern that resembles the immunodominance hierarchy 
induced by MVA in the primary response (  Fig. 1 B  ). This in-
dicates that VV-specifi  c T cells, which did not proliferate in 
recall responses to the virus, possibly lacked antigen-specifi  c 
stimulation. Impairment of viral antigen processing or presen-
tation might account for reduced or inhibited proliferation of 
T cells recognizing late gene product  –  derived epitopes during 
VV recall responses. To further analyze this issue, we decided 
to focus on the   H3L   late gene product. 
  Antigen presentation of late viral proteins 
is substantially delayed 
  As mentioned earlier, the viral life cycle of VV can be di-
vided into three distinct phases: early, intermediate, and late 
  Figure 3.     Antigen presentation of late viral proteins is delayed. 
Specifi  c   51  Cr release of MVA WT  –  infected (MOI 10) A375 target cells is 
shown (E/T ratio   10:1). (A) H3L  184 -specifi  c T cells do not substantially 
lyse infected target cells before 15 h after infection. (B) Peptide titration 
shows similar affinity of T cell lines, except for H3L  184  -specific T cells 
showing a higher affinity. (C) Infected LCL (MOI 10) was used for a 
  kinetic analysis to stimulate IFN-      production in several V V-specifi  c 
T cell lines. MVA WT  –  infected cells already stimulate B22R  79 -specifi  c 
(early gene) T cells 2 h after infection. H3L  184 -specifi  c (late gene) T cells 
get stimulated 6 h after infection. A6L  6  - and I1L  211 -specifi  c T cells (both 
late) or control cell line are not stimulated by MVA WT  –  infected cells. 
(D) LCL infected by recombinant virus MVA      H3L P7.5 H3L expressing 
the   H3L   gene under an early/late promoter rapidly induce IFN-     
  production in H3L  184 -specifi  c T cells. Data are representative of three 
independent experiments.     JEM VOL. 204, September 3, 2007 
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(Tyr  369  ;   Fig. 5  ).   35 d after prime, T cell frequencies in the 
peripheral blood were determined by tetramer analysis. There-
after, mice were boosted either with MVA WT or a recombinant 
virus expressing human tyrosinase under control of an early/
late promoter (MVA hTyr). 5 d later, we again measured the 
specifi  c T cell frequencies in the blood by tetramer staining. 
To compensate for variations of peptide-induced T cell fre-
quencies within individual mice, we calculated the ratio of the 
frequencies before and after boosting with MVA vaccines as a 
relative measure of T cell proliferation. When H3L  184  -specifi  c 
T cells were induced together with C7L  74  - or B22R  79  -specifi  c 
T cells, they did not proliferate after boosting with MVA WT 
(  Fig. 5  ). Importantly, when H3L  184  -specifi  c T cells were ac-
companied by irrelevant Tyr  369  -specifi  c T cells, they were 
readily amplifi  ed. However, when we boosted peptide-
specifi  c CD8      T cells with MVA hTyr expressing human ty-
rosinase under the control of an early/late promoter, the H3L  184  -
specifi  c response was again suppressed. These data demonstrate 
that the proliferation of H3L  184  -specifi  c T cells strongly de-
pends on the ability of participating T cells of other specifi  city 
to cross-compete. 
  T cells cross-compete early after priming 
  Because we observed cross-competition between T cells only 
during boost vaccinations, we hypothesized that this pheno-
menon is linked to the presence of T cells with fully devel-
oped eff  ector function. Naive T cells gain eff  ector function 
early (    3 d) during primary responses (  20  ). Furthermore, by 
using   L. monocytogenes  , it has been previously demonstrated 
that a second infection during the priming phase can induce 
typical recall responses (  21  ). We wanted to confi  rm our re-
sults by reimmunizing during the primary MVA response, 
T cells did not get activated by infected cells, even at 8 h 
after infection, despite similar functional affi   nity for peptide-
pulsed target cells (  Fig. 3 B  ). Coincubation of T cells with 
stimulators that had been infected for a longer period (up to 
14 h) did not lead to higher stimulation rates (unpublished 
data). H3L  184  -specifi  c T cells were activated as early as 6 h 
after infection (20%), and     40% of the T cells produced 
IFN-      at 8 h after infection. Notably, this T cell line has the 
highest functional affi   nity (  Fig. 3 B  ). We concluded from 
these data that presentation of determinants derived from 
late viral gene products to CD8  T cells is generally reduced 
and delayed for several hours compared with early viral 
gene products. 
  Timing of viral antigen expression regulates T cell expansion 
  Next, we wanted to analyze whether the delayed antigen 
presentation of late viral proteins is related to the impaired 
proliferation of T cells specifi  c for these proteins during boost 
vaccinations. We constructed a recombinant MVA in which 
the natural   H3L   gene has been knocked out (Fig. S5, available 
at http://www.jem.org/cgi/content/full/jem.20070849/DC1) 
and reinserted into the viral genome under the control 
of a promoter (P7.5) with early/late activity (MVA      H3L 
P7.5 H3L). Northern blot analysis revealed that both viruses 
MVA WT and MVA      H3L P7.5 H3L express the   H3L   gene 
at comparable levels; but, in contrast to MVA WT, MVA 
     H3L P7.5 H3L already produces the H3 protein early dur-
ing the viral life cycle (Fig. S6). In vitro, MVA      H3L P7.5 
H3L  –  infected target cells induced IFN-      in H3L  184  -specifi  c 
T cells very early after infection ( Fig. 3 D ). Importantly, H3L 184  -
specifi  c T cells were readily expanded in the secondary response 
when boosting with MVA      H3L P7.5 H3L (  Fig. 4 A  ).   
Thereby, the absolute numbers of H3L  184  -specifi  c T cells 
reached similar levels as B22R  79  -specifi  c T cells (  Fig. 4 B  ). Im-
portantly, the responses against other epitopes (A6L  6  , I1L  211  , 
and B22R  79  ) were comparable for both viruses (  Fig. 4   and 
not depicted). 
  Cross-competition of T cells regulates T cell expansion 
  Although epitopes derived from late viral proteins were pre-
sented with a strong delay on the surface of infected cells, one 
would expect that T cells recognizing these epitopes would 
eventually get stimulated and could proliferate. In vivo, how-
ever, H3L  184  - and I1L  211  -specifi  c T cells were not amplifi  ed 
during recall responses (  Fig. 2  ). Based on this observation, we 
speculated that in addition to the delayed presentation of viral 
late proteins, T cells with diff  erent specifi  cities compete for 
infected APCs. In particular, T cells recognizing VV-epitopes 
from early proteins should have an advantage to cross-compete 
compared with T cells recognizing VV-epitopes from late 
  proteins. Because peptide immunizations in HHD mice are very 
effi   cient (  19  ), we tried to experimentally address this question 
by priming naive mice simultaneously with pairs of peptides. 
Cohorts of mice were immunized with H3L  184   together with 
either B22R  79   or C7L  74,   which are both derived from early 
proteins, or a control peptide derived from human tyrosinase 
  Figure 4.     MVA      H3L P7.5 H3L amplifi  es H3L-specifi  c T cell 
responses. HHD mice were primed i.p. with 10  8   IU of MVA WT and boosted 
with MVA WT (shaded bar) or MVA      H3L P7.5 H3L (open bar). MVA     H3L 
P7.5 H3L induces a signifi  cant expansion of H3L  184 -specifi  c IFN-     – producing 
T cells compared with MVA WT, without altering the T cell response 
against B22R  79  . Relative (A) and absolute numbers (B) of IFN-     – producing, 
H3L  184 -specifi  c T cells measured in the spleen compared with MVA WT. 
Data are representative of three independent experiments.   n     4.     2192 CROSS-COMPETITION SHAPES IMMUNODOMINANCE HIERARCHY | Kastenmuller et al.
  Cross-competition between T cells specifi  c for early 
viral determinants 
  Thus far, we have shown that T cell cross-competition be-
tween T cells recognizing early or late viral products is func-
tionally important for shaping the immunodominance hierarchy 
during recall responses. Next, we wanted to analyze whether 
T cells recognizing early epitopes also cross-compete with each 
other. In C57BL/6 mice, the B8R  20  -specifi  c T cell response 
dominates both the primary and secondary response against VV. 
To analyze if B8R  20  -specifi  c T cells were cross-competing with 
T cells of other specifi  cities and impaired their expansion, we 
used MVA      B8R for prime/boost immunizations (Fig. S1). 
As anticipated, despite the absence of B8R  20  -specifi  c T cells, 
the expansion of A3L  270  -specifi  c T cells was suppressed in the 
recall response, presumably by cross-competing K3L  6  - and 
A8R  189  -specifi  c T cells, which rapidly expanded. Again, we 
found a switch in the immunodominance hierarchy favoring 
the proliferation of T cells recognizing epitopes derived from 
early gene products (  Fig. 7 A  ).   In contrast, in a prime/boost 
regimen using MVA WT, K3L  6  - and A8R  189  -specifi  c T cells 
were not amplifi   ed to the same level compared with MVA 
     B8R. To further characterize T cell cross-competition between 
T cells recognizing early viral products, we performed short 
interval prime/boost immunizations. We defi  ned the K3L  6  - and 
and thereby defi  ne a time point after priming when T cells 
are able to execute cross-competition. For a detailed kinetic 
analysis, mice were primed and subsequently revaccinated once 
from 1 to 6 d after prime (  Fig. 6 A  ).   6 d after revaccination, 
mice were killed, and the epitope dominance pattern was de-
termined and compared with mice that had received MVA only 
once. Interestingly, when mice were reimmunized 1 or 2 d after 
prime, the epitope pattern did not change. When reimmunizing 
at 1 d after prime, A6L  6  -, I1L  211  -, and H3L  184  -specifi  c CD8  
T cells even increased (  Fig. 6 B   and Fig. S7 B, available at 
http://www.jem.org/cgi/content/full/jem.20070849/DC1, 
for all epitopes). Reimmunization on day 2 did not alter 
the frequencies or absolute numbers of the diff  erent T cell 
populations. However, when boosting on day 3 or later, 
A6L  6  -, I1L  211  -, and H3L  184  -specifi  c T cell frequencies were 
reduced, whereas B22R  79  -specifi  c T cells expanded. From 
day 4 or later, B22R  79  -specifi  c T cells were signifi  cantly am-
plifi  ed, as seen in secondary responses after 35 d. To confi  rm 
that T cells were able to cross-compete early after primary 
infection, we revaccinated MVA WT  –  primed mice with MVA 
WT or MVA      H3L P7.5 H3L. Indeed, similar to boosting 
at day 35 (  Fig. 4  ), B22R  79  - and H3L  184  -specifi  c T cells expanded 
when mice were boosted early (day 5) with MVA      H3L 
P7.5 H3L (  Fig. 6 D   and Fig. S7 D). 
  Figure 5.     Cross-competition between T cells recognizing early and late determinants. HHD mice were simultaneously primed with pairs of peptides. 
35 d after prime, the frequencies of respective tetramer-specifi  c CD8  T cells in the peripheral blood were determined. Mice were boosted i.p. with 10  8   IU  of 
MVA WT or MVA hTyr. 5 d later, tetramer-specifi  c CD8  T cells were again measured in the blood. Numbers within dot plots indicate frequencies of H3L  184 -
specifi  c T cells before (left column) and after boosting (right column). Index shows relative increase of tetramer-specifi  c T cells after boosting. Black line indicates 
that frequencies before and after boost are equal (index   1). In contrast to control T cells (Tyr  369  ), the presence of B22R  79 -  or  C7L 74 -specifi  c T cells (both early 
genes) signifi  cantly suppresses the expansion of H3L  184  - (late gene) specifi  c T cells after boosting with MVA WT. However, when MVA hTyr is used the expansion 
of H3L  184 -specifi  c T cells is again suppressed, but Tyr  369 -specifi  c T cells are readily amplifi  ed. Data are representative of three independent experiments.   n     5.     JEM VOL. 204, September 3, 2007 
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  viruses expressing the model antigen OVA driven by a pro-
moter with exclusive early (MVA K1L OVA) or late (MVA 
P11 OVA) activity. As shown by Western blot analysis, in-
fection with MVA K1L OVA led to a rapid production of 
OVA, even in the presence of Ara-C, which is an eff  ective 
inhibitor of late viral gene expression. In contrast, the synthe-
sis of OVA in MVA P11 OVA  –  infected cells is initiated later 
during viral infection and abrogated upon Ara-C treatment 
(  Fig. 8 A  ).   After 24 h of infection, the overall amount of syn-
thesized OVA is higher in MVA P11 OVA  –  infected cells 
(Fig. S8, available at http://www.jem.org/cgi/content/full/jem
.20070849/DC1). Interestingly, when measuring the process-
ing and presentation of OVA by specifi  c staining of OVA  257  -
loaded MHC-I complexes on RMA cells, we found a clear 
correlation with the time of expression, which depends on 
the promoter activity of the respective constructs (  Fig. 8 B  ). 
2 h after infection, we could already detect a substantial 
A8R  189  -specifi  c T cell response induced by MVA      B8R as 
the baseline and considered A3L  270  -specifi  c T cell response as 
an internal control. We then compared the K3L  6  - and A8R  189  -
specifi  c T cell response induced by recombinant viruses, which 
contain an additional moderate (MVA OVA      B8R contain-
ing OVA  257  ) or highly (MVA WT containing B8R  20  ) immuno-
genic epitope or both (MVA OVA containing OVA  257   and 
B8R  20  ). As shown in   Fig. 7 B  , this stepwise additional induc-
tion of cross-competing T cells specifi  c for early viral epitopes 
(OVA  257  /B8R  20  ) leads to a gradually increased suppression of 
T cells specifi  c for other early viral epitopes (K3L  6  /A8R  189  ). 
Importantly, T cells specifi  c for late viral epitopes (A3L  270  ) 
remain fully suppressed. Hence, we conclude that cross-
competition is also functional among T cells specifi  c for early 
viral proteins during recall responses. 
  Timing of viral antigen expression is crucial 
for vaccination strategies 
  To investigate the infl  uence of viral antigen expression on 
T cell cross-competition more closely, we constructed two 
  Figure 6.     Competition between T cells occurs early after priming. 
HHD mice were primed with MVA WT and boosted with the same virus 
(A and B) early at indicated days after priming, or at day 5 with MVA     H3L 
P7.5 H3L (C and D). (A) Schematic of prime/boost regimen. (B) Intracellular 
cytokine staining of splenocytes, comparing the VV-specifi  c CD8  T cell 
responses after priming (shaded bar) or 6 d after boosting (open bar). 
B22R  79 -specifi  c T cells are signifi  cantly increased when boosting 4 d after 
prime or later. (C) Schematic of prime/boost regimen. (D) H3L  184 -specifi  c 
T cell responses can be signifi  cantly amplifi  ed when using MVA     H3L  P7.5 
H3L (open bar) as compared with MVA WT (closed bar). Data are summary 
of three independent experiments.   n      6.   
  Figure 7.     Early virus-specifi  c T cells suppress the expansion of 
early and late virus-specifi  c T cells. (A) Intracellular cytokine staining 
of splenocytes comparing MVA      B8R (open bar) with MVA WT (shaded 
bar) 6 d after homologous boost (day 35). Immunodominance hierarchy is 
changing in MVA      B8R  –  immunized mice favoring the expansion of K3L  6 - 
and A8R  189  - (both early genes) specifi  c T cells over A3L  270  - (late gene) 
specifi  c T cells in the absence of B8R  20 -specifi  c T cells. (B) Intracellular 
cytokine staining of splenocytes comparing MVA      B8R with MVA OVA 
P7.5      B8R, MVA WT, and MVA OVA P7.5 6 d after homologous boost (day 5). 
The expansion of K3L  6  - and A8R  189 -specifi  c (both early genes) T cells is 
successively suppressed by gradual appearance of cross-competing 
B8R  20 -  and  OVA 257 -specifi  c (both early genes) T cells, wheras A3L  270 -specifi  c 
(late gene) T cells remain fully suppressed. Data are representative of two 
independent experiments.   n     5.     2194 CROSS-COMPETITION SHAPES IMMUNODOMINANCE HIERARCHY | Kastenmuller et al.
with MVA P11 OVA could reduce the bacterial load only 
slightly better than mice immunized with MVA WT. 
    DISCUSSION   
  In our study, we identifi  ed T cell cross-competition to be 
responsible for the dramatic switch in the epitope dominance 
patterns of VV-specifi  c CD8  T cells by comparing primary 
with secondary infections. Changes in immunodominance 
hierarchies of T cells have also been reported for other path-
ogens, such as infl  uenza, herpes viruses, or LCMV (  22  –  24  ). 
In the LCMV infection model, these changes have been at-
tributed primarily to T cell exhaustion. In contrast, upon in-
fl  uenza virus infection, the changing epitope pattern has been 
attributed to diff  erential antigen expression, refl  ecting the ca-
pacity of memory T cells to respond to nondendritic cells (  9  ). 
Yewdell  ’  s group, which works extensively on immunodom-
inance in the infl  uenza model, recently challenged this inter-
pretation ( 8  ), and came to the conclusion that cross-presentation 
could also account for changes in dominance patterns. Further-
more, they demonstrated that immunodominance hierarchies 
were independent of perforin or Fas-mediated lysis in the 
secondary response, and are therefore not connected to APC 
killing or CD8  T cell cross-competition. La Gruta et al. ele-
gantly shifted epitopes within the same viral infection context 
to study immunodominance (  25  ). They found that the epit-
ope hierarchies were a result of antigen dose and the size of 
the preexisting T cell pool. Competitive interactions, as dem-
onstrated in our study, seemed to have only little impact in 
their model. Removal or addition of immunogenic epitopes 
in infl  uenza virus had no eff  ect during priming, but led to 
amount of H2-K  b   OVA  257   complexes on the surface of MVA 
K1L OVA  –  infected cells with a maximum at     12 h after 
  infection. In contrast, we could not detect minimal amounts of 
OVA  257   on the surface of MVA P11 OVA  –  infected RMA cells 
before 12 h after infection. In vivo, however, we found a com-
parable OVA-specifi  c T cell response in the spleen of MVA 
P11 OVA  –   and MVA K1L OVA  –  immunized mice (  Fig. 8 C  ). 
This implicates that during priming neither the amount of 
presented peptide/MHC-I complexes nor the time after in-
fection at which viral antigen expression occurs determines the 
outcome of the T cell response. However, during secondary 
immunizations only MVA K1L OVA  –  immunized mice readily 
amplifi  ed OVA  257  -specifi  c T cells, whereas MVA P11 OVA 
failed to expand OVA  257  -specifi  c T cells (  Fig. 8 C  ). Importantly, 
the T cell responses against virus-specifi  c antigens were com-
parable for both viruses (Fig. S8). These data suggest that the 
time of viral antigen expression is of minor importance for T cell 
priming, but highly relevant for shaping the immunodominance 
hierarchy in secondary immunizations. This observation is 
independent from the route of vaccination or the ability of 
VV to replicate. The reduced proliferation of T cells specifi  c 
for late viral proteins is founded on a delayed and impaired 
presentation of viral epitopes derived from these proteins. 
Additionally, these T cells are further inhibited to expand by 
other cross-competing T cells specifi  c for early viral proteins. 
This has important consequences concerning the protection 
against lethal pathogens after vaccination. Only MVA constructs 
expressing OVA early during the viral life cycle were able to 
induce a protective immunity in mice when challenged with le-
thal doses of   L. monocytogenes  -OVA (  Fig. 8 D  ). Mice immunized 
  Figure 8.     Timing of viral antigen expression is essential during secondary responses. (A) Western blot analysis of Hela cells infected with MVA 
K1L OVA or MVA P11 OVA in the presence (+) or absence (-) of Ara-C, which is a specifi  c inhibitor of late viral gene expression. Cell lysates were harvested 
at 0, 5, or 12 h after infection. (B) For relative quantifi  cation of SIINFEKL-K  b   complexes on infected cells, 25-D1.16 antibody was used. Mean fl  uorescence 
intensity of positive cells is shown. (C) Intracellular cytokine staining of splenocytes comparing MVA K1L OVA with MVA P11 OVA 8 d (shaded bar) after 
prime or 6 d (open bar) after boost, which was performed 35 d after priming with MVA P7.5 OVA, to allow for comparable memory T cell frequencies at 
the time of the second immunization. Mice were primed and boosted i.p. 5 d later with different MVA constructs. (D) 6 d after homologous boost, mice 
were challenged with different doses of   L. monocytogenes-  OVA (2       10 6     shaded bar; 5      1 0  5     open bar) i.v. and numbers of viable   L. monocytogenes  
in spleen were determined 2 d later. nd   not detectable.     JEM VOL. 204, September 3, 2007 
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  The primary response to the replication-competent VV 
strain CVA was similar compared with MVA, apart from a 
substantial response against B22R  79.   Interestingly, we could also 
induce and detect an increased B22R  79  -specifi  c response by 
performing short-interval prime/boost experiments with MVA. 
This, in a way, imitates replication caused by repeated infections 
during the priming phase. In that respect, the primary response 
to a replication-competent VV could be interpreted as a dy-
namic process of priming and boosting of T cells. This is in 
contrast to persistent chronic viral infections, where T cell ex-
haustion is a factor for changing immunodominance hierar-
chies. As recently shown, using LCMV as a model for a chronic 
viral infection, CD8  T cells undergo extensive peptide-
dependent division independent of IL-7 or -15. This suggests 
that these CD8  T cells go through a fundamentally diff  erent 
pattern of diff  erentiation compared with memory CD8  T cells 
that develop after an acute infection (  34  ). In addition to 
A*0201 transgenic mice, the suppression of secondary T cell 
responses against late viral epitopes by T cells recognizing early 
viral epitopes could also be confi  rmed in C57BL/6 mice, and 
seems to be a characteristic feature of VV infection. A similar 
connection between immunodominance and the kinetics 
of viral protein expression has been observed using LCMV 
(  24, 35  ). Indeed, in an elegant model using hemisplenectomized 
mice and analysis of TCR-      motifs, Bousso et al. found that 
the timing of recruitment of individual T cell clones con-
tributes more to the immune responses than their precursor 
frequency (  36  ). 
  In contrast to T cells specifi  c for H3L  184   or I1L  211  , which 
do not proliferate during secondary responses, the expansion 
of T cells specifi  c for A6L  6   is not fully suppressed when the 
boost is performed late in the memory phase (day 35). This 
might be explained by comparatively higher T cell numbers 
against A6L  6  , which cannot be controlled as easily by com-
peting T cells recognizing early epitopes. After short-interval 
prime/boost experiments (day 5), the A6L  6  -specifi  c T cell 
response is fully suppressed, possibly because during priming, 
the T cell size is increased compared with the memory phase 
(day 35), and therefore competition is enhanced. Neverthe-
less, we assume that the amount of B22R  79  -specifi  c T cells 
induced after priming is probably too low to completely out-
compete A6L  6  -, H3L  184  -, and I1L  211  -specifi  c T cells. Addi-
tionally,     2% B22R  79  -specifi  c T cells (  Fig. 2  ) cannot fully 
account for the total VV-specifi  c response after secondary 
immunization, which is     30  –  40% of all CD8  T cells (  11  ). 
Therefore, it is intriguing to speculate that one or more yet 
unidentifi  ed HLA-A*0201-restricted epitopes might exist. 
  It can be expected that T cells recognizing epitopes de-
rived from early viral proteins confer better protection against 
infection. Because VV replication is completed at     8 h after 
infection, T cells specifi  c for late viral proteins are likely to be 
activated too late to confer any protection because of delayed 
antigen presentation in infected cells. In this context, T cell 
cross-competition, and the subsequent preferential expansion 
of T cells specifi  c for early proteins, refl  ects the host  ’  s ambi-
tion to rapidly clear viral infections. We speculate that this 
compensation or suppression of other T cells during boosting, 
respectively (  26, 27  ). The authors attributed their fi  ndings to 
eff  ects of antibodies or limiting amounts of antigen. In our 
study, however, we could link the immunodominance pattern 
arising during secondary vaccinations to the presence of primed 
T cells. A reason for potential diff  erences between VV and 
other infectious agents could be the high-level gene expression 
promoted by VV, leading to high antigen amounts. Hence, 
competition mediated by limited antigenic resources seems to 
be unlikely. Consistent with that view, a mathematical model 
of T cell competition recently predicted that a large set of dif-
ferent epitopes, such as that found for VV infection, should 
decrease T cell competition (  28  ). However, under these con-
ditions, high affi   nity of T cells and high expression levels of 
single epitopes would increase the chances for T cell competi-
tion. Hence, when immunizing with VV, the APC itself or 
resources of the APC other than the peptide  –  MHC complexes 
may become the limiting factor for competing T cells. Besides 
costimulatory or adhesion molecules, this could involve cyto-
kines or access to APC. Another possibility is that memory T 
cells could be able to silence APCs after a certain number of 
interactions. Further work will be necessary to elucidate the 
cellular and molecular basis of T cell cross-competition. 
  Surprisingly, T cell cross-competition has been rarely 
documented so far. Marrack  ’  s group demonstrated T cell 
cross-competition by using peptide-pulsed DC and trans-
ferred TCR transgenic T cells (  29  ). They found that the de-
gree of competition depended on the affi   nity of responding 
T cells, but was much less effi   cient than competition among 
T cells with the same epitope specifi  city (  30  ). In the LCMV 
model, T cell cross-competition is believed to be function-
ally unimportant (  5  ). However, in this particular study, cross-
competition was only analyzed during the priming phase. 
Our work demonstrates that cross-competition toward VV is 
active during the secondary response and depends on imme-
diate T cell eff  ector function (presence of primed T cells). 
This notion is supported by Kedl et al., who succeeded in 
demonstrating T cell cross-competition by using primed T cells 
(  29  ). Additionally, we found that T cells were able to cross-
compete 3 d after priming. This correlates with the develop-
ment of cytotoxicity of naive T cells after exposure to APCs, 
which was detectable after 48 h and was fully present after 72 h 
(  20  ). In a bacterial model, Wong and Pamer showed that 
CTL activity developed within 72 h, and that these T cells 
probably eliminated APCs, thereby regulating antigen pre-
sentation and, consequently, T cell priming and expansion (  31  ). 
Interestingly, Belz et al. recently showed that during sec-
ondary infl  uenza infections, T cells terminate the antigen 
presentation in a perforin-dependent manner (  32  ). However, 
in the infl  uenza model, perforin, granzyme B, or FAS  –  FASL 
interaction did not seem to infl  uence the immunodominance 
hierarchy (  7, 8  ). Other models showed that early onset of 
IFN-      production by CD8  T cells correlated with the 
immunodominant responses ( 33  ). Further work will be neces-
sary to defi  ne which features of eff  ector T cells are crucial to 
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the Cytofi  x/Cytoperm kit (BD Biosciences) according to the manufacturer  ’  s 
recommendations. Data were acquired by FACS analysis on a FACSCanto 
(BD Biosciences) and analyzed with FlowJo software (Tree Star, Inc.). 
  Northern blot analysis.     Cells were infected with MVA WT or MVA 
     H3L P7.5 H3L at multiplicity of infection (MOI) 10. Total RNA was iso-
lated with guanidinium hydrochloride and ultracentrifugation over a CsCl 
cushion and separated by electrophoresis in 1% agarose glyoxal gels. Sub-
sequently, RNA was transferred onto positively charged nylon membranes 
(Zeta-Probe; Bio-Rad Laboratories). Riboprobe for detection of MVA-
encoded mRNA 093L (H3L) was obtained by excision of H3L DNA from 
the transfer plasmid (pIII-     HR-P7.5) using PmeI and BamH1 restriction 
enzymes. In vitro RNA labeling, hybridization, and signal detection were per-
formed according to the manufacturer  ’  s instructions (Rediprime II Random 
Prime Labeling System; GE Healthcare), applying 68  °  C for hybridization 
and high-stringency wash in 1      SSC containing 0.1% SDS buff  er. 
  Western blot analysis.     Expression of OVA was confi  rmed by Western blot 
analysis of cell lysates from infected cells. For some experiments, infections 
were performed in the presence of cytosine      -D-arabinofuranoside (Ara-C; 
Sigma-Aldrich) at 40      g/ml to restrict the VV-specifi  c gene expression to the 
early phase of the viral replication cycle. Proteins were resolved by electro-
phoresis on a SDS 10% polyacrylamide gel and electroblotted onto nitrocel-
lulose for 20 min in a buff  er containing 48 mM Tris, 39 mM glycine, 0.037% 
SDS, and 20% ethanol, pH 8.3. The blots were blocked overnight on ice in 
a tris-buff  ered saline blocking buff  er containing 1% bovine serum albumin, 
0.1% Tween-20, and 0.02% NaN  3  , and incubated for 1 h at room tempera-
ture with an OVA-specifi  c antibody (rabbit polyclonal to OVA; Abcam) 
diluted 10,000-fold in blocking buff  er. As a control, blots were incubated at 
similar dilutions with mouse anti  –       -actin antibody (AC-15; Sigma-Aldrich). 
Blots were washed with 0.1% Tween-20 in tris-buff  ered saline, and incu-
bated for 1 h at RT with POD-conjugated goat polyclonal anti  –  rabbit IgG 
(Dianova GmbH) diluted 15,000-fold, washed, incubated with chemilumi-
nescent substrate (Lumi-Light; Roche), and exposed to a photographic fi  lm 
(BioMax; Kodak). For      -actin detection, POD-conjugated goat polyclonal 
anti  –  mouse IgG+IgM (Dianova) was used at the same dilution. 
  Chromium release assays.     Specifi  c lysis by A*0201-restricted murine CTL 
reactive against human tyrosinase peptide 369  –  377 or against VV-specifi  c pep-
tide A6L  6  , B22R  79  , H3L  184  , or I1L  211   was determined in a 6-h standard   51  Cr 
release assay, as previously described (  10  ). In brief, HLA-A*0201  –  positive 
A375 or RL-LCL cells were infected at MOI 10, washed, and labeled for 1 h 
at 37  °  C with 100   μ  Ci Na  51  CrO  4  , and then washed four times. Labeled target 
cells were plated in U-bottomed 96-well plates at 10  4   cells/well and incubated 
for 6 h with eff  ector cells at various E/T ratios. The specifi  c   51  Cr release was 
determined in supernatants. 
  Antigen presentation assays.     RL-LCL cells were infected for 30 min at 
MOI 10 on ice and shifted on 37  °  C. At indicated time points, cells were co-
cultured at diff  erent ratios with peptide-specifi  c CTL lines in the presence of 
1 mg/ml BFA (Sigma-Aldrich) for 5 h. Staining and analysis for intracellular 
IFN-     -production was performed as described above. For OVA  257   presenta-
tion, RMA cells were infected for 30 min at MOI 20 on ice and then shifted 
on 37  °  C. At indicated time points, cells were harvested and stained with anti-
SIINFEKL-Kb antibody (25-D1.16). 
  Statistical analysis.     All statistical analysis was performed using Excel Software. 
Results are expressed as the mean       the SD. Diff  erences between groups were 
analyzed for statistical signifi  cance using two-tailed student   t   test. 
  Online supplemental material.     Fig. S1 shows the construction of B8R-
defi  cient MVA. Fig. S2 shows the multistep viral growth curve on CEF cells. 
Fig. S3 shows that the immunodominance hierarchy is changed after second-
ary immunization in HHD mice. Fig. S4 shows IFN-      production of VV-
specifi  c T cells from freshly isolated splenocytes of MVA WT (10  7   IU)-primed 
fi  nding might also apply to other large DNA viruses, such as 
herpes viruses. Interestingly, a recent study analyzing T cells 
in CMV-infected humans described that the number of im-
mediate early protein 1  –  specifi  c (IE-1), and not pp65-specifi  c 
(a late viral protein), T cells correlated with protection from 
disease (  37  ). 
  In summary, we have demonstrated that the expansion 
of virus-specifi  c CD8  T cells was regulated by T cell cross-
  competition favoring T cells that are able to rapidly detect 
  infected cells. Therefore, the outcome of this competition was 
heavily infl  uenced by the timing of antigen expression, but in-
dependent of the route of vaccination or the ability of a virus 
to replicate. In immunotherapy using recombinant viral vec-
tors, a successful expansion of the desired T cell response can be 
strongly impaired by cross-competing, vector-specifi  c T cells. 
We show that this impairment can be compensated by express-
ing target antigens early during the viral life cycle, allowing 
antigen-specifi  c T cells to successfully cross-compete. Thereby, 
we are able to improve the T cell responses against target anti-
gens and simultaneously decrease the vector-specifi  c response. 
The identifi  cation of other factors determining the outcome 
of T cell cross-competition and, ultimately, the elucidation 
of the molecular and cellular mechanism behind T cell cross-
competition will allow for designing improved vaccines. 
    MATERIALS AND METHODS   
  Mice and vaccination.     HLA-A*0201-transgenic, H2D  b    / ,      2m  / , 
HHD mice (  38  ) or C57BL/6 mice were derived from in-house breeding under 
specifi  c pathogen-free conditions following institutional guidelines. Only female 
mice between 8 and 12 wk of age were used. Mice were vaccinated with 10  7   
or 10  8   IU MVA. For peptide vaccination, mice were immunized s.c. with 0.1 mg 
peptide and 10 ng of synthetic CpG1668. Mice were killed on the indicated 
days after vaccination, and spleens were harvested to be analyzed by ICS. 
  Cell lines.     RMA cells were provided by F.A. Lemonnier (Institute Pasteur, 
Paris, France). Lymphoblastoid B cell line RL-LCL (HLA-A*0201 positive) 
was established in our laboratory, A375 human melanoma cells (CRL-1619) 
were purchased from American Type Culture Collection. Cell lines were 
cultured with RPMI 1640 supplemented with 10% FCS, 100 U/ml penicillin, 
and 100      g/ml streptomycin. 
  Viruses.     The VV strains New York City Board of Health (Wyeth) and 
Western Reserve (WR) were provided by B. Moss (National Institutes of 
Health, Bethesda, MD). CVA at second passage on chicken embryo fi  bro-
blasts (CEFs) or MVA (cloned isolate F6) at 582nd passage on CEF were 
used for this study. Replication-competent VV and MVA were routinely 
propagated and titered following standard methodology (  39  ). 
  Quantifi  cation of antigen-specifi  c CD8 T cell responses.     Splenocytes 
from vaccinated HHD-mice were stimulated with either the HLA-A*0201 
restricted human tyrosinase peptide Tyr  369  , Her-2/neu  435  , the vaccinia-  specifi  c 
peptides derived from H3L  184  , A6L  6  , I1L  211  , D12L  251  , C7L  74  , B22R  79   (  13  ), 
or a control peptide (Flu M1  58  ) for 5 h. C57BL/6 mice were stimulated with 
either H-2Kb  –   or H-2Db  –  restricted VV-specifi   c peptides derived from 
A3L  270  , A8R  189  , B8R  20  , K3L  6  , OVA  257   (  13  ), or a control peptide (     -Gal  96  ) 
for 5 h. 1 mg/ml Brefeldin A (Sigma-Aldrich) was present throughout stimu-
lation. Cells were live/dead-stained with ethidium monoazide bromide 
  (Invitrogen) and blocked with anti-CD16/CD32-Fc-Block (BD Biosciences). 
Surface markers were stained with APC-conjugated anti-CD8      and PE-
  conjugated anti-CD62L (Caltag Laboratories). Intracellular cytokine staining 
for IFN-      production was performed with FITC anti  –  IFN-      (XMG1.2) using JEM VOL. 204, September 3, 2007 
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